Successful treatment of lymphoproliferative disease complicating primary immunodeficiency/immunodysregulatory disorders with reduced-intensity allogeneic stem-cell transplantation

Blood

Volumn 110, Issue 6, 2007, Pages 2209-2214

  Cohen, Jonathan M ^a,b   Sebire, Neil J ^a   Harvey, Julia ^a   Gaspar, H Bobby ^a,b   Cathy, Cale ^a   Jones, Alison ^a   Rao, Kanchan ^a   Cubitt, David ^c   Amrolia, Persis J ^a,b   Davies, E Graham ^a,b   Veys, Paul ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Department of Neurosurgery   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; AZITHROMYCIN; BLEOMYCIN; CARMUSTINE; CHLORAMBUCIL; CIPROFLOXACIN; CISPLATIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; IMMUNOGLOBULIN; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PAROMOMYCIN; PENICILLIN V; PREDNISOLONE; PROCARBAZINE; RITUXIMAB; STEROID; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CERVICAL LYMPHADENOPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; CRYPTOSPORIDIOSIS; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; IMMUNE DEFICIENCY; IMMUNE DYSREGULATION; INFECTION; INFECTION PREVENTION; LYMPHOPROLIFERATIVE DISEASE; MALE; PRIORITY JOURNAL; RETINITIS; VIREMIA; VIRUS LOAD;

EID: 34548847157     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-12-062174     Document Type: Article

References (29)

1. Knowles DM. Immunodeficiency-associated lymphoproliferative disorders. Mod Pathol. 1999;12:200-217.
2. Canioni D, Jabado N, MacIntyre E, et al. Lymphoproliferative disorders in children with primary immunodeficiencies: immunological status may be more predictive of the outcome than other criteria. Histopathology. 2001;38:146-159.
3. Frizzera G. Atypical lymphoproliferative disorders. In: Knowles DM, Mitchell CW, Satterfield TS, eds. Neoplastic Hematopathology. Baltimore: Williams & Wilkins. 1992;459-495.
4. Filipovich AH, Shapiro R, Robison L. Lymphoproliferative disorders associated with immunodeficiency. In: Magrath IT, ed. The non-Hodgkin's Lymphomas. London: Edward Arnold. 1990;135-154.
5. Rao K, Amrolia PJ, Jones A, et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood. 2005;105:879-885.
6. Cohen J, Gandhi M, Naik P, et al. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning. Br J Haematol. 2005;129:229-239.
7. Hertzberg M, Grigg A, Gottlieb D, et al. Reduced-intensity allogeneic haemopoietic stem cell transplantation induces durable responses in patients with chronic B-lymphoproliferative disorders. Bone Marrow Transplant. 2006;37:923-928.
8. van Esser JWJ, Niesters HGM, van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood. 2002;99:4364-4369.
9. Rooney CM, Smith CA, Ng CYC, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92:1549-1555.
10. Sebire NJ, Haselden S, Malone M, Davies EG, Ramsay AD. Isolated EBV lymphoproliferative disease in a child with Wiskott-Aldrich syndrome manifesting as cutaneous lymphomatoid granulomatosis and responsive to anti-CD20 immunotherapy. J Clin Pathol. 2003;56:555-557.
11. Amrolia P, Gaspar HB, Hassan A, et al. Nonmyeloablative stem cell transplantation for congenital immunodeficiencies. Blood. 2000;96:1239-1246.
12. Shroff R, Trompeter R, Cubitt D, Thaker U, Rees L. Epstein-Barr virus monitoring in paediatric renal transplant recipients. Pediatr. Nephrol. 2002;17:770-775.
13. Wagner HJ, Cheng YC, Huls MH, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood. 2004;103:3979-3981.
14. Nichols KE, Ma CS, Cannons JL, Schwartzberg PL, Tangye SG. Molecular and cellular pathogenesis of X-linked lymphoproliferative disease. Immunol Rev. 2005;203:180-199.
15. Gilmour KC, Gaspar HB. Pathogenesis and diagnosis of X-linked lymphoproliferative disease. Expert Rev Mol Diagn. 2003;3:549-561.
16. Worth A, Thrasher AJ, Gaspar HB. Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype. Br J Haematol. 2006;133:124-140.
17. Dianzani U, Chiocchetti A, Ramenghi U. Role of inherited defects decreasing Fas function in autoimmunity. Life Sci. 2003;72:2803-2824.
18. Thapar N, Shah N, Ramsay AD, Lindley KJ, Milla PJ. Long-term outcome of intractable ulcerating enterocolitis of infancy. J Pediatr Gastroenterol Nutr. 2005;40:582-588.
19. Borisch B, Raphael M, Swerdlow SH, Jaffe ES. Lymphoproliferative diseases associated with primary immune disorders. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organisation Classification of Tumours: Tumours of the Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:257-259.
20. Harris NL, Swerdlow SH, Frizzera G, Knowles DM. Posttransplant lymphoproliferative disorders. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organisation Classification of Tumours: Tumours of the Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:264-269.
21. Pinkerton CR, Hann I, Weston CL, et al. Immunodeficiency-related lymphoproliferative disorders: prospective data from the United Kingdom Children's Cancer Study Group Registry. Br J Haematol. 2002;118:456-461.
22. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002;99:4357-4363.
23. + T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood. 2003;101:4290-4297.
24. Chakrabarti S, Milligan DW, Pillay D, et al. Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation. Blood. 2003;102:839-842.
25. Cohen JM, Cooper N, Chakrabarti S, et al. EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning. Leuk Lymphoma. 2007;48:256-269.
26. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995;345:9-13.
27. Khanna R, Bell S, Sherritt M, et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci U S A. 1999;96:10391-10396.
28. Slatter MA, Bhattacharya A, Abinun M, et al. Outcome of boost haemopoietic stem cell transplant for decreased donor chimerism or graft dysfunction in primary immunodeficiency. Bone Marrow Transplant. 2005;35:683-689.
29. Lankester AC, Visser LF, Hartwig NG, et al. Allogeneic stem cell transplantation in X-linked lymphoproliferative disease: two cases in one family and review of the literature. Bone Marrow Transplant. 2005;36:99-105.